EClinicalMedicine. 2026 Jul 18;98:104059. doi: 10.1016/j.eclinm.2026.104059. eCollection 2026 Aug.
ABSTRACT
BACKGROUND: In parallel with diagnostic advances and awareness of cardiac amyloidosis (CA) in aging populations, frailty is increasingly observed in CA. However, the relationship between the frailty and CA remains poorly characterized owing to limited studies that have defined frailty a priori. We performed a meta-analysis to characterize the impact of frailty on clinical and functional patient outcomes in CA.
METHODS: Systematic review of four electronic databases was performed for all studies reporting frailty prevalence, functional and clinical endpoints in patients with CA from January 2015 to April 2026 (CRD420251152212). Frailty was classified based on individual study scoring systems. The primary outcome of interest was all-cause mortality, expressed as pooled hazard (HR) or risk ratios (RR) with 95% confidence intervals (CI) using inverse-variance random-effects models. Other outcomes included hospitalizations, quality of life, functional status (6-min walk distance [6MWD]), and prescription of disease modifying treatment. Heterogeneity was summarized using the I2 statistic; study quality was rated with the Newcastle-Ottawa Scale; and certainty of evidence was graded using the GRADE framework. Leave-one-out sensitivity analyses and visual funnel plots were performed where applicable.
FINDINGS: Fifteen studies with a total of 5048 patients, predominantly (>95%) with transthyretin amyloid cardiomyopathy (ATTR-CM), were included. The prevalence of frailty ranged between 6.7% and 75% across studies with a pooled mean of 33.9% (826/2435 frail). Pooling 2141 patients with outcomes available, both pre-frailty (RR 2.22, 95% CI 1.37-3.60, p < 0.01) and frailty (RR 3.93, 95% CI 2.09-7.40, p < 0.01) significantly associated with increased risks of all-cause mortality after adjustment for age and frailty assessment tool. 6MWD, a functional surrogate of frailty, predicted poorer outcomes both using baseline 6MWD (<350/300 m: HR 2.22, 95% CI 1.15-4.31, p = 0.02) and 1-year interval change in 6MWD (>35 reduction: HR 1.80, 95% CI 1.52-2.14; >5% reduction: HR 1.89, 95% CI 1.60-2.23; both p < 0.01). Beyond mortality, frailty also predicted increased risk of functional decline, poorer quality of life, and reduced prescription of disease-modifying treatment.
INTERPRETATION: Patients with ATTR-CM and frailty have higher mortality risk, poorer functional outcomes and reduced prescription of disease-modifying treatment compared to those without frailty. Findings were consistent across frailty instruments and sensitivity analyses, supporting the incorporation of routine frailty assessment and 6MWD into clinical management of ATTR amyloidosis.
FUNDING: None.
PMID:42495106 | PMC:PMC13393012 | DOI:10.1016/j.eclinm.2026.104059